Pricing and Reimbursement of Hospital Drugs in the US

Pricing and Reimbursement of Hospital Drugs in the US

Brand level analysis of the latest trends in US government hospital drug funding and the companies and brands benefitting most
Since the Obama reforms, Medicare Part B hospital drug expenditure has grown from $28.4 billion in 2017 to $40.1 billion in 2021. The average expenditure per beneficiary has risen from $818 in 2017 to $1275 in 2021. But which companies are benefiting? Which brands are growing the fastest? What therapy areas are most impacted? This analysis report takes a deep dive into the data of 36 brands to expose the trends that are shaping this critical area of US drug funding.

Companies

Amgen, Novartis, Lilly, Roche, GlaxoSmithKline, AstraZeneca, Regeneron, Janssen Biotech, UCB, Merck Sharp & Dohme, Merck & Co., Bristol Myers Squibb, Genentech, Astellas, Takeda, Seagen, Alexion, Johnson & Johnson, Celgene, Fresenius Kabi, Abraxis BioScience, Apotex, Onyx Pharmaceuticals